Primary Biliary Cirrhosis

Carlo Selmi, Ian R. Mackay, M. Eric Gershwin

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) affects primarily middle-aged women and is characterized by chronic cholestasis and the presence in serum of high-titer antimitochondrial autoantibodies (AMA). The disease leads to the destruction of the intrahepatic bile ducts and progressive fibrosis. The diagnosis is made when two out of three criteria are met, i.e., positive serum AMA, alkaline phosphatase elevation, and compatible liver histology. Like other autoimmune diseases, the onset of PBC seems to depend on the cumulative effects of some susceptibility genes and the effects of environmental agents, infectious or chemical. Genome-wide association studies strongly point to the genes of the IL-12 pathway, among others. The association of AMA, identified as autoantibody directed against the E2 subunit of the mitochondrial pyruvate complex (PDC-E2), with biliary ductular lesions, is enigmatic, but it is suspected that PDC-E2 during degradation undergoes faulty apoptosis with production of a disease-inducing apotope. The presence in nearly 50% of cases of atypical PBC-related antinuclear antibodies remains a mystery. Treatment with the now-approved ursodeoxycholic acid is surprisingly effective. Several informative transgene-based mouse models have been developed and confirm the nexus between AMA reactivity and cholangiocyte destruction, and experimental models are available supporting the participation in pathogenesis of environmental xenobiotics. Possible tracks towards an understanding of the "cause" of PBC can be visualized.

Original languageEnglish (US)
Title of host publicationThe Autoimmune Diseases: Fifth Edition
PublisherElsevier Inc.
Pages909-924
Number of pages16
ISBN (Print)9780123849298
DOIs
StatePublished - Dec 2013

Fingerprint

Biliary Liver Cirrhosis
Autoantibodies
Intrahepatic Bile Ducts
Ursodeoxycholic Acid
Genome-Wide Association Study
Antinuclear Antibodies
Cholestasis
Xenobiotics
Interleukin-12
Serum
Pyruvic Acid
Transgenes
Genes
Autoimmune Diseases
Alkaline Phosphatase
Histology
Fibrosis
Theoretical Models
Apoptosis
Liver

Keywords

  • Antimitochondrial antibody
  • Antinuclear antibody
  • Autoimmune cholangitis
  • Human leukocyte antigen
  • Interleukin-12
  • Molecular mimicry
  • Pruritus
  • Ursodeoxycholic acid
  • Xenobiotics

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Selmi, C., Mackay, I. R., & Gershwin, M. E. (2013). Primary Biliary Cirrhosis. In The Autoimmune Diseases: Fifth Edition (pp. 909-924). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-384929-8.00062-9

Primary Biliary Cirrhosis. / Selmi, Carlo; Mackay, Ian R.; Gershwin, M. Eric.

The Autoimmune Diseases: Fifth Edition. Elsevier Inc., 2013. p. 909-924.

Research output: Chapter in Book/Report/Conference proceedingChapter

Selmi, C, Mackay, IR & Gershwin, ME 2013, Primary Biliary Cirrhosis. in The Autoimmune Diseases: Fifth Edition. Elsevier Inc., pp. 909-924. https://doi.org/10.1016/B978-0-12-384929-8.00062-9
Selmi C, Mackay IR, Gershwin ME. Primary Biliary Cirrhosis. In The Autoimmune Diseases: Fifth Edition. Elsevier Inc. 2013. p. 909-924 https://doi.org/10.1016/B978-0-12-384929-8.00062-9
Selmi, Carlo ; Mackay, Ian R. ; Gershwin, M. Eric. / Primary Biliary Cirrhosis. The Autoimmune Diseases: Fifth Edition. Elsevier Inc., 2013. pp. 909-924
@inbook{91f6d35aa2a24b958071a42b158fb29f,
title = "Primary Biliary Cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) affects primarily middle-aged women and is characterized by chronic cholestasis and the presence in serum of high-titer antimitochondrial autoantibodies (AMA). The disease leads to the destruction of the intrahepatic bile ducts and progressive fibrosis. The diagnosis is made when two out of three criteria are met, i.e., positive serum AMA, alkaline phosphatase elevation, and compatible liver histology. Like other autoimmune diseases, the onset of PBC seems to depend on the cumulative effects of some susceptibility genes and the effects of environmental agents, infectious or chemical. Genome-wide association studies strongly point to the genes of the IL-12 pathway, among others. The association of AMA, identified as autoantibody directed against the E2 subunit of the mitochondrial pyruvate complex (PDC-E2), with biliary ductular lesions, is enigmatic, but it is suspected that PDC-E2 during degradation undergoes faulty apoptosis with production of a disease-inducing apotope. The presence in nearly 50{\%} of cases of atypical PBC-related antinuclear antibodies remains a mystery. Treatment with the now-approved ursodeoxycholic acid is surprisingly effective. Several informative transgene-based mouse models have been developed and confirm the nexus between AMA reactivity and cholangiocyte destruction, and experimental models are available supporting the participation in pathogenesis of environmental xenobiotics. Possible tracks towards an understanding of the {"}cause{"} of PBC can be visualized.",
keywords = "Antimitochondrial antibody, Antinuclear antibody, Autoimmune cholangitis, Human leukocyte antigen, Interleukin-12, Molecular mimicry, Pruritus, Ursodeoxycholic acid, Xenobiotics",
author = "Carlo Selmi and Mackay, {Ian R.} and Gershwin, {M. Eric}",
year = "2013",
month = "12",
doi = "10.1016/B978-0-12-384929-8.00062-9",
language = "English (US)",
isbn = "9780123849298",
pages = "909--924",
booktitle = "The Autoimmune Diseases: Fifth Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Primary Biliary Cirrhosis

AU - Selmi, Carlo

AU - Mackay, Ian R.

AU - Gershwin, M. Eric

PY - 2013/12

Y1 - 2013/12

N2 - Primary biliary cirrhosis (PBC) affects primarily middle-aged women and is characterized by chronic cholestasis and the presence in serum of high-titer antimitochondrial autoantibodies (AMA). The disease leads to the destruction of the intrahepatic bile ducts and progressive fibrosis. The diagnosis is made when two out of three criteria are met, i.e., positive serum AMA, alkaline phosphatase elevation, and compatible liver histology. Like other autoimmune diseases, the onset of PBC seems to depend on the cumulative effects of some susceptibility genes and the effects of environmental agents, infectious or chemical. Genome-wide association studies strongly point to the genes of the IL-12 pathway, among others. The association of AMA, identified as autoantibody directed against the E2 subunit of the mitochondrial pyruvate complex (PDC-E2), with biliary ductular lesions, is enigmatic, but it is suspected that PDC-E2 during degradation undergoes faulty apoptosis with production of a disease-inducing apotope. The presence in nearly 50% of cases of atypical PBC-related antinuclear antibodies remains a mystery. Treatment with the now-approved ursodeoxycholic acid is surprisingly effective. Several informative transgene-based mouse models have been developed and confirm the nexus between AMA reactivity and cholangiocyte destruction, and experimental models are available supporting the participation in pathogenesis of environmental xenobiotics. Possible tracks towards an understanding of the "cause" of PBC can be visualized.

AB - Primary biliary cirrhosis (PBC) affects primarily middle-aged women and is characterized by chronic cholestasis and the presence in serum of high-titer antimitochondrial autoantibodies (AMA). The disease leads to the destruction of the intrahepatic bile ducts and progressive fibrosis. The diagnosis is made when two out of three criteria are met, i.e., positive serum AMA, alkaline phosphatase elevation, and compatible liver histology. Like other autoimmune diseases, the onset of PBC seems to depend on the cumulative effects of some susceptibility genes and the effects of environmental agents, infectious or chemical. Genome-wide association studies strongly point to the genes of the IL-12 pathway, among others. The association of AMA, identified as autoantibody directed against the E2 subunit of the mitochondrial pyruvate complex (PDC-E2), with biliary ductular lesions, is enigmatic, but it is suspected that PDC-E2 during degradation undergoes faulty apoptosis with production of a disease-inducing apotope. The presence in nearly 50% of cases of atypical PBC-related antinuclear antibodies remains a mystery. Treatment with the now-approved ursodeoxycholic acid is surprisingly effective. Several informative transgene-based mouse models have been developed and confirm the nexus between AMA reactivity and cholangiocyte destruction, and experimental models are available supporting the participation in pathogenesis of environmental xenobiotics. Possible tracks towards an understanding of the "cause" of PBC can be visualized.

KW - Antimitochondrial antibody

KW - Antinuclear antibody

KW - Autoimmune cholangitis

KW - Human leukocyte antigen

KW - Interleukin-12

KW - Molecular mimicry

KW - Pruritus

KW - Ursodeoxycholic acid

KW - Xenobiotics

UR - http://www.scopus.com/inward/record.url?scp=84902605501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902605501&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-384929-8.00062-9

DO - 10.1016/B978-0-12-384929-8.00062-9

M3 - Chapter

AN - SCOPUS:84902605501

SN - 9780123849298

SP - 909

EP - 924

BT - The Autoimmune Diseases: Fifth Edition

PB - Elsevier Inc.

ER -